{"title":"Adjunctive Brivaracetam in Early Treatment Line Combinations: 12-Month Real-World Experience and Impact on Health Outcomes in Adult Patients with Focal Seizures.","authors":"Susanne Knake, Marco de Curtis, Eliane Kobayashi, Teresa Lema-Facal, Louis-Georges Maillard, Ludovic Ampe, Bonita Réhel, Sylvain Rheims, Anne-Liv Schulz, Iryna Leunikava","doi":"10.1007/s40801-026-00592-4","DOIUrl":"https://doi.org/10.1007/s40801-026-00592-4","url":null,"abstract":"<p><strong>Background: </strong>Postmarketing data for adjunctive brivaracetam (BRV) suggest potential benefit in earlier antiseizure medication (ASM) regimens.</p><p><strong>Objective: </strong>We aimed to evaluate real-world effectiveness of BRV in earlier ASM therapy lines (over ~12 months) in patients with focal seizures with/without focal to bilateral tonic-clonic seizures (primary objective) and assess patient characteristics, health outcomes, and tolerability.</p><p><strong>Methods: </strong>Prospective, postmarketing, noninterventional study of adjunctive BRV in Europe/Canada (December 2020-January 2024; BRITOBA/EP0103). Selection criteria are adults (≥ 18 years) with history of focal seizures, no prior BRV treatment, and ≤ 3 lifetime (prior/at BRV initiation) ASMs when initiating adjunctive BRV.</p><p><strong>Results: </strong>A total of 392 patients received ≥ 1 BRV dose (mean age 44.9 years; mean lifetime ASMs 2.0). Of 298 patients, 41.9% were seizure-free for ≥ 6 consecutive months during up to ~12 months' observation. At 12 months, 20.5% of 254 patients were seizure-free from baseline, 75.7% of 292 achieved ≥ 50% focal seizure reduction from baseline, 75.5% of 392 remained on BRV, and 72.0% of 289 and 66.8% of 211 had improved (minimally/much/very much) on Clinical Global Impression of Change and Patient's Global Impression of Change. From baseline to 12 months, Ten-Item Patient-Weighted Quality of Life in Epilepsy Inventory (QOLIE-10-P) total score improved by a mean of 9.9 points (n = 152); Nine-Item Treatment Satisfaction Questionnaire for Medication effectiveness, convenience, and global satisfaction scores improved by a mean of 21.6 (n = 144), 6.1 (n = 146), and 19.1 (n = 145) points; Work Productivity and Activity Impairment Questionnaire: General Health scores showed numerical mean improvements in percentages of activity impairment due to health problem (-14.0 [n = 157]), work time missed due to health problem (-12.3 [n = 50]), impairment while working due to health problem (-7.8 [n = 63]), and overall work impairment due to health problem (-9.0 [n = 48]); and the Neurological Disorders Depression Inventory in Epilepsy score improved by a mean of -1.1 points (n = 158). Seizure Severity Questionnaire (questions 5 and 8 only) showed numerically fewer reports of postictal cognitive effects (37.0% of 135 patients versus 63.6% of 308) and improved median seizure severity score (2.0 [n = 124] versus 4.0 points [n = 301]) at 12 months versus baseline. Of 392 patients, 13.8% experienced ≥ 1 drug-related treatment-emergent adverse event (TEAE), 9.4% discontinued BRV due to TEAEs.</p><p><strong>Conclusions: </strong>In adults with focal seizures, BRV in earlier ASM regimens was effective and well tolerated. At 12 months, there were improvements in quality of life, clinical condition, work productivity, and treatment satisfaction.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Health and Economic Burden of Severe Respiratory Syncytial Virus Infections Among Older Adults in Japan: A Retrospective Administrative Database Study.","authors":"Shoko Akiyama, Yu-Fan Ho, Victor Preckler, Taizo Matsuki, Lauriane Harrington, Akiko Mizukami","doi":"10.1007/s40801-026-00588-0","DOIUrl":"https://doi.org/10.1007/s40801-026-00588-0","url":null,"abstract":"<p><strong>Background: </strong>Respiratory syncytial virus (RSV) is a leading cause of acute respiratory illness and severe outcomes in older adults.</p><p><strong>Objective: </strong>This retrospective cohort study investigated the health and economic burden of medically attended RSV infections among adults ≥ 60 years in Japan.</p><p><strong>Methods: </strong>Data were collected between 1 September 2008 and 31 August 2021 from the Medical Data Vision (MDV) hospital-based claims database and the insurance-based JMDC database. We investigated RSV-related complications during the first episode. Healthcare resource utilization (HCRU) and medical costs were compared between baseline (pre-event: 30-day average costs during the 365 days before RSV diagnosis) and post-event (30 days after RSV diagnosis); differences were explored using paired sample t-tests (p < 0.05).</p><p><strong>Results: </strong>A total of 178 cases identified between 2009 and 2019 were included in the study, 144 were from the MDV database (mean age 74 years) and 34 from the JMDC database (mean age 64 years). RSV-related complications were recorded in 61.1% and 55.9% of the MDV and JMDC cohorts, respectively. HCRU in the MDV cohort increased significantly from pre- to post-event (average number of outpatient visits per case: 1.21 to 2.07; average number of hospitalizations per case: 0.07 to 0.37), resulting in significant additional medical costs of ¥196,231 (p < 0.001).</p><p><strong>Conclusions: </strong>Medically attended RSV infections were associated with substantial short-term increases in HCRU and total medical costs among older adults in Japan. These findings may help inform prevention strategies for severe RSV disease.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-World Effectiveness and Utilisation of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in a Public Healthcare System.","authors":"Guillermo Tarrasó, Miriam Umbria, Noelia Paco, Roser Vives, Montserrat Gasol, Antonio Vallano","doi":"10.1007/s40801-026-00585-3","DOIUrl":"https://doi.org/10.1007/s40801-026-00585-3","url":null,"abstract":"<p><strong>Background: </strong>Anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies represent an important therapeutic advance in migraine prevention. However, evidence on their effectiveness and use in routine clinical practice within public healthcare systems remains limited.</p><p><strong>Objective: </strong>To evaluate real-world effectiveness, utilisation patterns, and associated pharmaceutical expenditure of anti-CGRP monoclonal antibodies for migraine prevention in routine clinical practice within Catalan public healthcare system.</p><p><strong>Methods: </strong>A retrospective population-based cohort study was conducted using administrative and clinical registry data from the Catalan Health Service (2019-2023). Adult patients treated with erenumab, fremanezumab or galcanezumab were included. Clinical effectiveness was assessed based on reduction in monthly migraine days and acute medication use. Utilisation patterns and pharmaceutical expenditure were analysed using healthcare billing data.</p><p><strong>Results: </strong>Between 2019 and 2023, 5438 patients received 7270 treatment episodes, with a marked increase in treatment initiation over time. Of the 4902 evaluable treatment episodes at 3 months, 48% of treatments achieved a ≥ 50% reduction in monthly migraine days, and 57.4% achieved ≥ 30% reduction. At 9 months, complete response was observed in 58.9% of the 2779 evaluable treatments episodes. Mean (SD) monthly migraine days decreased from 16.68 (7.47) at baseline to 9.09 (7.31) at 9 months. Acute medication use decreased by 40%. Treatment uptake increased substantially, with rising pharmaceutical expenditure and a 33% increase in mean annual cost per patient.</p><p><strong>Conclusions: </strong>Anti-CGRP monoclonal antibodies demonstrate sustained real-world effectiveness in migraine prevention and are associated with reduced migraine burden and acute medication use. Within a publicly funded healthcare system, their increasing uptake highlights the value of monitoring real-world outcomes, utilisation patterns and associated pharmaceutical expenditure to support appropriate and sustainable use in clinical practice.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149332898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Caregiver Experiences with Daily and Weekly Growth Hormone Injections in Japanese Children: A Cross-sectional Survey.","authors":"Kei Takasawa, Takahiro Sato, Nozomi Ebata, Yaoki Sonohara, Ryosuke Nishi","doi":"10.1007/s40801-026-00595-1","DOIUrl":"https://doi.org/10.1007/s40801-026-00595-1","url":null,"abstract":"<p><strong>Purpose: </strong>Little is known about the treatment experience of patients with pediatric growth hormone deficiency (pGHD) and their caregivers in Japan after the approval of once-weekly growth hormone (GH) injections. This study aimed to assess the treatment experience, unmet needs, and treatment satisfaction of patients with pGHD and their caregivers who were administering once-daily or once-weekly GH injections.</p><p><strong>Methods: </strong>A cross-sectional online survey using Japanese consumer panels was conducted from 14th June 2024 to 24th June 2024. Caregivers who had administered GH injections for ≥ 3 months to patients with pGHD aged 3-14 years were surveyed. In addition to between-group comparisons by injection frequency, a multivariable logistic regression analysis adjusted for confounding factors was conducted to identify factors associated with the desire to change injection frequency.</p><p><strong>Results: </strong>A total of 187 eligible caregivers (once-daily cohort, n = 137; once-weekly cohort, n = 50) participated in the study. The top three unmet needs of caregivers were injection pain (35.8%), effectiveness (29.4%), and injection frequency (26.2%). The once-daily cohort had higher proportions of caregivers who desired to change the injection frequency (47.4% versus 22.0%, p = 0.002) and who cited having no chance to switch as a reason for the current injection frequency (27.7% versus 10.0%, p = 0.011) compared with the once-weekly cohort. There were no significant differences between the once-daily cohort and the once-weekly cohort in terms of perceived injection pain or treatment satisfaction assessed by Treatment Satisfaction Questionnaire for Medication version II (TSQM v. II) from the caregiver's perspective. Multivariable logistic regression analysis showed that current once-daily administration was an independent factor associated with the desire to change (adjusted odds ratio [aOR] 5.30, 95% confidence interval [CI] 2.22-13.7, p < 0.001).</p><p><strong>Conclusions: </strong>These findings suggest that the once-daily cohort may be missing opportunities to re-evaluate their current treatment regimen. To optimize the treatment experiences and quality of life for patients and caregivers, it is necessary to promote shared decision-making (SDM) for regular treatment reviews. However, given the cross-sectional design of this study, these findings represent associations rather than causal relationships.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minjee Park, Angela Ting, Aaksa Nair, Alexandria Harrold, Mohita Kumar
{"title":"Characterization of Patients Living with Generalized Myasthenia Gravis Initiating Rozanolixizumab in the USA.","authors":"Minjee Park, Angela Ting, Aaksa Nair, Alexandria Harrold, Mohita Kumar","doi":"10.1007/s40801-026-00590-6","DOIUrl":"https://doi.org/10.1007/s40801-026-00590-6","url":null,"abstract":"<p><strong>Background: </strong>Rozanolixizumab is a neonatal fragment crystallizable receptor blocker approved to treat adults with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive (Ab+) generalized myasthenia gravis (MG) in the USA.</p><p><strong>Objectives: </strong>This retrospective, observational cohort study aimed to understand the profile of patients initiating rozanolixizumab treatment in the USA.</p><p><strong>Methods: </strong>Adults with MG who enrolled in a patient support program (ONWARD™) and/or had specialty pharmacy data were included. Descriptive analysis of de-identified data (July 2023-February 2025) was conducted to summarize patient, disease and treatment characteristics, rozanolixizumab use at baseline, and rozanolixizumab use patterns during follow-up.</p><p><strong>Results: </strong>This study included 877 patients, of whom 51.5% were female. Mean (standard deviation [SD]) age was 62.2 (16.6) years; median (range) body weight was 87.0 (36-180) kg. Most patients had MG Foundation of America Clinical Class II or III (38.3% and 46.2%, respectively); 73.1% had anti-AChR Ab+ MG; 15.1% had anti-MuSK Ab+ MG. Baseline mean (SD) MG Activities of Daily Living score (n = 695) was 8.4 (3.8). Most patients (98.3%; n = 578/588) were naïve to rozanolixizumab. The mean (SD) follow-up for patients with ≥ 1 additional treatment date (n = 393) was 33.5 (19.1) weeks. Patients with ≥ 1 year of follow-up since rozanolixizumab initiation (n = 100) started a mean 3.7 cycles in year 1, comparable to the mean 4.1 cycles observed in Phase 3 studies.</p><p><strong>Conclusions: </strong>In the USA, rozanolixizumab treatment has been initiated in a broad population of patients with MG, with treatment patterns generally consistent with clinical trials.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149319041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Disproportionality Analysis of Acute Kidney Injury Reports Associated with Sacubitril/Valsartan (ARNI) in the Japanese Adverse Drug Event Report Database.","authors":"Kazuya Urashima, Tooru Ueda, Yoko Urashima, Mayuko Tamura-Takaori, Ayumi Fujimoto, Saori Tanaka, Yuka Kohda, Fumiaki Kitazawa, Ryuji Kato","doi":"10.1007/s40801-026-00593-3","DOIUrl":"https://doi.org/10.1007/s40801-026-00593-3","url":null,"abstract":"<p><strong>Background: </strong>Prescriptions of angiotensin receptor neprilysin inhibitor (ARNI) have increased in recent years; however, few pharmacovigilance studies have investigated acute kidney injury (AKI) reporting associated with ARNI. This study evaluated the disproportionate AKI reporting associated with ARNI in the Japanese Adverse Drug Event Report (JADER) database, compared AKI reporting between reports involving ARNI and valsartan, and explored the factors associated with AKI reporting among reports involving ARNI.</p><p><strong>Methods: </strong>Reports published in JADER between April 2020 and August 2023 were analyzed. AKI was identified using the narrow and broad scope Preferred Terms of the Standardized MedDRA Query (SMQ) \"acute renal failure\" (SMQ:20000003). The reporting odds ratios (RORs) and 95% confidence intervals (CIs) were calculated for ARNI and valsartan. Multivariable logistic regression analyses were performed to estimate adjusted RORs (aRORs) for sex, age, heart failure (HF), diabetes mellitus, chronic kidney disease (CKD), concomitant diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs). An additional adjusted analysis directly compared AKI reports between ARNI and valsartan.</p><p><strong>Results: </strong>A disproportionality signal for AKI was identified in the reports involving ARNI (ROR 7.11, 95% CI 6.27-8.07). Multivariable logistic regression showed that HF (aROR 1.68, 95% CI 1.22-2.31; p = 0.002) and CKD (aROR 2.17, 95% CI 1.60-2.93; p < 0.001) were independently associated with increased AKI reporting among reports involving ARNI. In the adjusted direct comparison, reports involving ARNI had higher odds of AKI reporting than those involving valsartan (aROR 2.03, 95% CI 1.50-2.74).</p><p><strong>Conclusions: </strong>Disproportionate AKI reporting signals were identified in reports involving ARNI in the JADER database. HF and CKD were independently associated with increased AKI reporting after adjustment. These findings have provided additional pharmacovigilance evidence regarding ARNI-associated AKI in Japan and should be interpreted in light of the inherent limitations of spontaneous reporting data.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Filip Z Jovčić, Miloš N Milosavljević, Milena Cmiljanić, Ana V Pejčić, Srđan M Stefanović
{"title":"Effects of Interventions for Delabeling Penicillin Allergy in Hospitalized Patients: A Systematic Review.","authors":"Filip Z Jovčić, Miloš N Milosavljević, Milena Cmiljanić, Ana V Pejčić, Srđan M Stefanović","doi":"10.1007/s40801-026-00594-2","DOIUrl":"https://doi.org/10.1007/s40801-026-00594-2","url":null,"abstract":"<p><strong>Background and objective: </strong>Penicillin allergy labels are common among hospitalized patients, yet most represent inaccurate or nonimmune-mediated reactions and may contribute to suboptimal antibiotic prescribing. This systematic review aimed to evaluate the effectiveness and safety of hospital-based penicillin allergy delabeling interventions and their impact on antibiotic prescribing.</p><p><strong>Methods: </strong>PubMed/MEDLINE, CENTRAL, Scopus, and Web of Science were systematically searched up to January 2026. Additional records were identified through ClinicalTrials.gov and citation tracking. Eligible studies included hospitalized patients with documented penicillin or β-lactam allergy labels who underwent structured delabeling interventions with a comparator group. Given substantial heterogeneity in study design, interventions, and outcomes, findings were synthesized narratively.</p><p><strong>Results: </strong>Nine studies were included (three randomized controlled trials and six nonrandomized studies). Delabeling success rates ranged from approximately 4% to over 95%, depending on intervention approach, risk of bias, and local workflows. The greatest success was observed in interventions using direct oral challenge for patients at low risk of true penicillin allergy. Pharmacist-led and antimicrobial stewardship-based interventions also effectively identified inaccurate allergy labels and supported safe delabeling. Adverse events were uncommon and predominantly mild. Delabeling was associated with improved prescribing practices, including greater use of narrow-spectrum β-lactams.</p><p><strong>Conclusions: </strong>Hospital-based penicillin allergy delabeling interventions appear safe and locally effective when implemented within structured clinical pathways. However, the current evidence base is structurally fragmented, and extreme clinical and methodological heterogeneity limits the formulation of universal hospital protocols. Standardized, multi-center randomized controlled trials are urgently needed to establish uniform risk stratification algorithms and outcome metrics.</p><p><strong>Prospero registration number: </strong>CRD420251246346.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Avery R Hammersmith, Ismaeel Yunusa, Chao Cai, Bryan L Love
{"title":"Eluxadoline Utilization in Medicare Part D, 2016-23: National Trends, Geographic Variation, Prescriber-Type Patterns, and Spending.","authors":"Avery R Hammersmith, Ismaeel Yunusa, Chao Cai, Bryan L Love","doi":"10.1007/s40801-026-00587-1","DOIUrl":"https://doi.org/10.1007/s40801-026-00587-1","url":null,"abstract":"<p><strong>Background: </strong>Eluxadoline is a US Food and Drug Administration-approved therapy for irritable bowel syndrome with diarrhea and has important contraindications that may influence uptake in older adults. Medicare Part D dispensing patterns remain poorly characterized.</p><p><strong>Objective: </strong>This study aimed to characterize national and state-level trends in eluxadoline dispensing and spending in Medicare Part D from 2016-2023, including geographic variation in population-adjusted rates and differences in dispensing intensity by prescriber type.</p><p><strong>Methods: </strong>We conducted a retrospective repeated cross-sectional analysis using Centers for Medicare & Medicaid Services Medicare Part D Prescribers-by Provider and Drug Public Use Files from 2016 to 2023. Utilization was summarized using standardized 30-day fills (primary) and claims (secondary); state intensity was measured as fills per 100,000 Part D utilizers. Geographic concentration and outliers in state rates were assessed using Gini coefficients and median absolute deviation-based outlier detection. Prescriber-type differences in dispensing intensity were evaluated with negative binomial models of claims with National Provider Identifier-clustered standard errors.</p><p><strong>Results: </strong>The Public Use Files contained 7826 prescriber-year observations from 3866 prescribers. National 30-day fills rose from 4410.9 (2016) to 19,860.2 (2018) and declined to 15,326.0 (2023). Median state rates increased from 7.3 per 100,000 (2016) to 43.7 (2018) and were 27.6-35.9 in 2019-23; California, Texas, New Jersey, New York, and Florida accounted for 39.5% of fills. State utilizer counts correlated with total fills (ρ 0.80-0.89) more than adjusted rates (ρ 0.03-0.34). Geographic concentration remained moderate in 2018-23 (Gini 0.307-0.352), and New Jersey was a recurrent high-rate outlier. Gastroenterologists comprised 41.5-57.4% of prescribers and had higher claim intensity than primary care (incidence rate ratio 1.17, 95% confidence interval 1.13-1.21). Inflation-adjusted cost per standardized fill increased from $1021 to $1414.</p><p><strong>Conclusions: </strong>Eluxadoline dispensing in Medicare Part D is geographically concentrated and heterogeneous, with higher intensity among gastroenterologists. These descriptive benchmarks may inform medication-use monitoring, access and coverage evaluation, and future beneficiary-level studies of safety and appropriateness in irritable bowel syndrome with diarrhea care.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Polypharmacy and Activities of Daily Living in Older Patients Undergoing Cerebrovascular Rehabilitation: An Observational Study Using Japanese Real-World Data.","authors":"Yukari Ogawa, Takeshi Horii, Masaharu Sakoh, Kiyoshi Mihara","doi":"10.1007/s40801-026-00589-z","DOIUrl":"https://doi.org/10.1007/s40801-026-00589-z","url":null,"abstract":"<p><strong>Background: </strong>Polypharmacy is highly prevalent among older patients undergoing cerebrovascular rehabilitation and may adversely affect functional recovery.</p><p><strong>Objective: </strong>This study examined the association between polypharmacy and the extent and pace of functional recovery in older patients undergoing convalescent rehabilitation after cerebrovascular events.</p><p><strong>Methods: </strong>This retrospective observational study used a Japanese real-world claims database (Japan Medical Data Center claims database, accessed on 25 August 2025), and included patients aged ≥ 65 years admitted to convalescent rehabilitation wards for cerebrovascular diseases. Polypharmacy was defined as the use of six or more medications. Patients were categorized into four groups according to polypharmacy status at admission and discharge: persistent non-polypharmacy, polypharmacy resolved, incident polypharmacy, and persistent polypharmacy. Functional outcomes were assessed using the Functional Independence Measure (FIM). The primary outcome measure was FIM gain, and the secondary outcome measure was FIM efficiency. Multivariable linear regression analyses adjusted for patient characteristics, comorbidities, and hospital bed capacity were performed.</p><p><strong>Results: </strong>Among 44,980 patients, 48.9% had persistent polypharmacy and 14.8% developed incident polypharmacy during hospitalization. Polypharmacy status was not significantly associated with FIM gain. In contrast, FIM efficiency was significantly lower in the polypharmacy-resolved, incident polypharmacy, and persistent polypharmacy groups than in the persistent non-polypharmacy group. The strongest negative association with FIM efficiency was observed in the incident polypharmacy group (B = -0.114, p < 0.001), followed by the persistent polypharmacy group (B = -0.069, p < 0.001).</p><p><strong>Conclusions: </strong>Polypharmacy status was not significantly associated with FIM gain, the primary outcome. Although the three polypharmacy groups had lower FIM efficiency and longer hospital stays than the persistent non-polypharmacy group, the lower FIM efficiency may partly reflect differences in length of hospital stay. These observational findings do not establish a causal relationship between changes in medication burden and functional recovery.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Real-World Epidemiology of Inflammatory Bowel Disease in Italy: Treatment Patterns, Adherence, and Costs in Patients with Ulcerative Colitis Treated with Mesalazine.","authors":"Luca Degli Esposti, Chiara Veronesi, Silvia Calabria, Lisa Giannessi, Antonietta Barbieri, Fausto Bartolini, Stefania Dell'Orco, Fulvio Ferrante, Stefano Grego, Cataldo Procacci, Cristina Bezzio, Alessandro Armuzzi","doi":"10.1007/s40801-026-00591-5","DOIUrl":"https://doi.org/10.1007/s40801-026-00591-5","url":null,"abstract":"<p><strong>Background/aim: </strong>Ulcerative colitis (UC) and Crohn's disease (CD) are chronic immune-mediated conditions associated with a substantial clinical and economic burden. Italian epidemiological evidence is limited. Mesalazine remains a cornerstone of UC management. This study aimed to provide updated epidemiological estimates of inflammatory bowel disease (IBD) in Italy, and to evaluate real-world treatment patterns, adherence to oral mesalazine, and healthcare costs among patients with UC initiating mesalazine therapy.</p><p><strong>Methods: </strong>A retrospective observational analysis was conducted using Italian administrative databases covering ~4 million beneficiaries. Patients with UC and CD were identified (January 2010-May 2023) using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or exemption codes. Patients with UC who were new users of mesalazine were characterized at baseline. Mesalazine treatment patterns, adherence, and direct healthcare costs were described at follow-up.</p><p><strong>Results: </strong>At the end of 2023, UC and CD prevalence rates were 272 (95% confidence interval [CI] 267-278) and 166/100,000 (95% CI 162-170) inhabitants, respectively. Incidence rates in 2023 of UC and CD were 18.9 (95% CI 18-20) and 10.8/100,000 (95% CI 10-12), respectively. Among 2552 patients with UC who were new mesalazine users, 69.6% of time-dependent mesalazine users were adherent (versus 56.1% pH-dependent users). Mean annual cost per patients with UC who were new mesalazine users in 2023 was €4516, mainly driven by hospitalizations.</p><p><strong>Conclusions: </strong>This real-world analysis provides recent epidemiological estimates of UC and CD, and describes a substantial economic burden, highlighting the need for improving adherence and therapeutic pathways.</p>","PeriodicalId":11282,"journal":{"name":"Drugs - Real World Outcomes","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}